Amicus Therapeutics, Inc.

Symbol: FOLD

NASDAQ

10.4

USD

Market price today

  • -20.1432

    P/E Ratio

  • -0.2119

    PEG Ratio

  • 3.08B

    MRK Cap

  • 0.00%

    DIV Yield

Amicus Therapeutics, Inc. (FOLD) Financial Statements

On the chart you can see the default numbers in dynamics for Amicus Therapeutics, Inc. (FOLD). Companys revenue shows the average of 82.563 M which is 2.107 % gowth. The average gross profit for the whole period is 73.385 M which is 2.112 %. The average gross profit ratio is 0.711 %. The net income growth for the company last year performance is -0.359 % which equals -0.515 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Amicus Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.074. In the realm of current assets, FOLD clocks in at 483.061 in the reporting currency. A significant portion of these assets, precisely 286.2, is held in cash and short-term investments. This segment shows a change of -0.025% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 3.083, if any, in the reporting currency. This indicates a difference of -28.336% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 387.858 in the reporting currency. This figure signifies a year_over_year change of -0.016%. Shareholder value, as depicted by the total shareholder equity, is valued at 160.174 in the reporting currency. The year over year change in this aspect is 0.302%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 87.632, with an inventory valuation of 59.7, and goodwill valued at 197.8, if any. The total intangible assets, if present, are valued at 20.49. Account payables and short-term debt are 15.12 and 8.32, respectively. The total debt is 445.06, with a net debt of 198.06. Other current liabilities amount to 131.81, adding to the total liabilities of 617.71. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052003

balance-sheet.row.cash-and-short-term-investments

1099.23286.2293.6482.5
483.3
452.7
504.2
358.6
330.4
214
151.7
82
99.1
55.7
107.4
78.2
121.1
161.5
54.7
24.4
0

balance-sheet.row.short-term-investments

217.0139.2144.8237.3
320
309.9
424.4
309.5
143.3
144.5
127.6
38.4
65.2
30
77.9
58.9
93.1
117.3
42.6
18
0

balance-sheet.row.net-receivables

292.8687.666.252.7
46.9
33.3
22
9.5
1.3
0
0
0.8
3.2
5
0
0
0
0
0
0
0

balance-sheet.row.inventory

195.0259.723.826.8
19.6
14
8.4
4.6
3.4
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

191.7349.540.234.8
29.7
20
16.6
19.3
5
2.6
2.9
5.5
2.3
5.9
2.2
2.3
2.5
1.5
0.3
0.4
0

balance-sheet.row.total-current-assets

1778.84483.1423.8596.8
579.5
520.1
551.1
392
340.1
216.6
154.6
88.3
104.6
66.6
109.7
80.5
123.6
163
55
24.9
0

balance-sheet.row.property-plant-equipment-net

236.735860.363.1
67.2
81
11.4
9.1
9.8
6.2
2.8
4.1
5
2.4
2.6
4.4
4.9
3.8
4.4
3.3
0

balance-sheet.row.goodwill

791.19197.8197.8197.8
197.8
197.8
197.8
197.8
197.8
197.8
11.6
11.6
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

86.9220.52323
23
23
23
23
486.7
486.7
23
23
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

878.11218.3220.8220.8
220.8
220.8
220.8
220.8
684.5
684.5
34.6
34.6
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

13.443.14.3-4.9
-4.9
-5.1
-6.5
-6.5
-173.8
0
17.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

-10.3604.94.9
4.9
5.1
6.5
6.5
173.8
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

75.8215.51024.4
19.1
28.3
6.7
5.2
2.5
1.1
0.5
0.6
0.4
0.7
0.3
0.5
0.3
0.3
0.3
0.5
0

balance-sheet.row.total-non-current-assets

1193.74294.8300.4308.3
307.1
330.1
238.9
235.1
696.8
691.8
55.4
39.3
5.5
3.1
2.9
4.9
5.2
4.1
4.6
3.8
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.5

balance-sheet.row.total-assets

2972.58777.9724.2905.1
886.5
850.2
790
627
1036.8
908.4
210
127.6
110.1
69.8
112.6
85.4
128.8
167.1
59.6
28.7
0.5

balance-sheet.row.account-payables

76.7615.115.421.5
17.1
120.4
80.6
7.9
41
16.5
16.3
2.1
8.8
2.6
0
0
8.8
0.5
1.2
0.9
0

balance-sheet.row.short-term-debt

31.938.38.67.4
6.9
7.2
0
0.3
0.3
0
3.8
0.3
0.4
1
1.3
1.6
0.9
1.5
1.3
0.3
0

balance-sheet.row.tax-payables

12.4312.45.96.2
11.2
7.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

1722.72387.9443.6432.7
434.9
203
321.7
164.2
154.5
41.6
10.5
14.2
0.3
0
1
2.3
0.3
1.2
2.3
0.7
0

Deferred Revenue Non Current

17.7204.77.3
24.3
31.6
29.9
31.2
235.5
269.1
47.3
47.3
0
19
25.6
0
44
46.8
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

-17.72---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

513.63131.8110.1117.1
104.2
0
5.5
61.9
0.3
57.1
10.5
8
6.7
7.1
8.3
9.6
0
9.9
7.7
1.4
0

balance-sheet.row.total-non-current-liabilities

1830.25450462.1451.8
470.5
245
360.9
204.1
565.7
486.9
67.6
71.4
31.6
20.9
31.4
2.3
44.4
48
127
61.9
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5.8

balance-sheet.row.capital-lease-obligations

227.2748.960.150.8
52.5
60.7
0
0.3
0.3
0
0
0
0
0
0
0.4
0.3
1.2
2.3
0.7
0

balance-sheet.row.total-liab

2465.01617.7601.1597.8
600.1
373.8
447
274.2
676.7
560.5
87.8
81.8
40.9
40.2
47.6
13.5
57.7
63.8
137.2
64.5
5.8

balance-sheet.row.preferred-stock

6.77000
0
0
0
0
778.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

11.482.92.82.8
2.6
2.6
1.9
1.7
1.5
1.3
1
0.7
0.6
0.4
0.4
0.3
0.3
0.3
0.1
0
0

balance-sheet.row.retained-earnings

-10548.38-2684.1-2532.5-2295.9
-2045.5
-1768.6
-1412.2
-1063.6
-779.6
-579.6
-447.4
-378.5
-318.9
-270.1
-225.7
-170.8
-164.2
-124.8
-83.7
-37.3
-8.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

-4.045.3-12.15
8.2
2.8
0.1
-2.1
2
-0.1
-0.1
0
0
0
0
0
0.5
0.4
0
-2.6
0

balance-sheet.row.other-total-stockholders-equity

11041.7328362664.82595.5
2321
2239.6
1753.1
1416.8
358.1
926.2
568.7
423.6
387.5
299.3
290.2
242.3
234.4
227.4
6.1
4
3.2

balance-sheet.row.total-stockholders-equity

507.56160.2123307.4
286.4
476.4
342.9
352.9
360.2
347.8
122.2
45.8
69.2
29.6
64.9
71.8
71
103.3
-77.5
-35.8
-5.3

balance-sheet.row.total-liabilities-and-stockholders-equity

2972.58777.9724.2905.1
886.5
850.2
790
627
1036.8
908.4
210
127.6
110.1
69.8
112.6
85.4
128.8
167.1
59.6
28.7
0.5

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

507.56160.2123307.4
286.4
476.4
342.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

2972.58---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

220.0942.3144.8237.3
320
309.9
424.4
309.5
143.3
144.5
145.1
38.4
65.2
30
77.9
58.9
93.1
117.3
42.6
18
0

balance-sheet.row.total-debt

1803.53445.1452.1440.1
441.7
210.2
321.7
164.5
154.5
41.6
14.3
14.5
0.7
1
2.3
3.9
1.2
2.7
3.6
1
0

balance-sheet.row.net-debt

921.3198.1303.3194.9
278.5
67.4
242
115.4
-32.6
-27.9
-9.7
-29.2
-33.3
-24.6
-27.2
-15.4
-26.9
-41.5
-8.6
-5.4
0

Cash Flow Statement

The financial landscape of Amicus Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.551. The company recently extended its share capital by issuing 103.21, marking a difference of 3.659 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 49.2 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 98064000.000 in the reporting currency. This is a shift of 0.062 from the previous year. In the same period, the company recorded 7.87, 0, and -20.96, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -20.57, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005

cash-flows.row.net-income

-151.58-151.6-236.6-250.5
-276.9
-356.4
-349
-284
-200
-132.1
-68.9
-59.6
-48.8
-44.4
-54.9
-6.6
-39.4
-41.2
-46.3
-20

cash-flows.row.depreciation-and-amortization

7.877.95.36.2
8.8
4.8
4.2
3.6
3.2
1.8
1.5
1.7
1.7
1.6
2.1
2.1
1.5
1.2
1
0.7

cash-flows.row.deferred-income-tax

-9.97-4.900
-0.2
-1.4
6
-167.3
-3.7
1
0
-0.9
0
0
0.1
0
-6.4
-2.8
0
0

cash-flows.row.stock-based-compensation

86.0886.176.557.8
49.2
44.4
29.3
23.1
17.5
10
6
6.2
6.2
8.7
6.2
7.8
6.4
2.8
0
0

cash-flows.row.change-in-working-capital

-40.05-48-39.9-18.6
-32.1
11.6
-4.7
-25.8
1.1
14.3
9.4
4.9
7.8
-12.5
31.2
-46.9
-5.5
51
7
0.8

cash-flows.row.account-receivables

-20.11-20.1-17.3-8.2
-11.2
-11.1
-13.3
-7.7
-1.4
0
1.1
2.5
1.8
0
0
0
0
0
0
0

cash-flows.row.inventory

-44.61-44.6-5.3-7.8
-4.6
-5.1
-4.2
-0.9
-3.7
0
2.3
-3.2
3.6
0
0
0
0
0
0
0

cash-flows.row.account-payables

49.1949.2-6.47.4
-10.6
46.7
17.1
12.6
7.1
15.5
6.2
-0.6
-0.9
-1.3
-1.3
-1.7
-1.7
6.6
0
0

cash-flows.row.other-working-capital

-24.53-32.5-10.8-10
-5.6
-18.9
-4.3
-29.7
-0.9
-1.1
-0.2
6.3
3.2
-11.2
32.5
-45.2
-3.8
44.4
7
0.8

cash-flows.row.other-non-cash-items

38.5741.5282.5
17.8
46.6
14.3
234.9
31.4
4.9
0.3
2
-0.6
-2.8
1.4
0.2
6.4
4.1
4.5
0.4

cash-flows.row.net-cash-provided-by-operating-activities

-69.09000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-7.44-7.4-3.8-3.9
-3.2
-20
-6.3
-4.5
-6
-4.8
-0.2
-0.7
-4.3
-1.4
-0.4
-1.8
-2.7
-0.7
-2
-3

cash-flows.row.acquisitions-net

-12.203.43.9
3.2
20
6.3
0
0
-141.1
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-91.72-91.7-243.3-341.4
-365.2
-383.9
-578.4
-490.5
-219.9
-289.6
-162.8
-56.6
-118.5
-50.6
-113.7
-98.2
-153.7
-200.7
-62
-17

cash-flows.row.sales-maturities-of-investments

197.23197.2335.9424
354.8
499
463.5
323.8
221.4
290.1
55.9
83.3
83.4
98.5
94.6
131.8
178.1
126.4
37.4
3.1

cash-flows.row.other-investing-activites

12.200-3.9
-3.2
-20
-6.3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

98.0698.192.378.8
-13.6
95.2
-121.2
-171.2
-4.5
-145.3
-107.1
26.1
-39.4
46.5
-19.4
31.9
21.7
-75
-26.6
-16.9

cash-flows.row.debt-repayment

-20.96-21-0.3-0.5
-155.3
-0.4
-0.3
-0.3
-80.2
-15.3
-0.3
-0.4
-1.3
-1.3
-1.6
-1
0
0
0
0

cash-flows.row.common-stock-issued

95.35103.24.3199.8
42.3
189
294.6
243
97.1
243
135.8
15
80.2
45.2
45.2
0
0.5
92.8
63.6
40.4

cash-flows.row.common-stock-repurchased

-17.920-11.5-15
-10
-3.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

00-4.3-15
-32.3
-3.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

7.19-20.64.342.8
418.2
35.4
156.5
4.7
255.8
63.1
3.7
14.8
2.6
-44.9
0
3.8
-1.5
-0.8
2.5
0.8

cash-flows.row.net-cash-used-provided-by-financing-activities

61.6861.7-7.5212.1
262.9
217.5
450.8
247.4
272.7
290.9
139.2
29.4
81.5
-0.9
43.7
2.8
-1
91.9
66.2
41.3

cash-flows.row.effect-of-forex-changes-on-cash

6.316.3-14.6-5
3.8
1.7
1.5
1.3
-0.1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

96.8398.2-96.383.3
19.8
64
31.1
-138
117.5
45.4
-19.6
9.7
8.3
-3.9
10.2
-8.7
-16.1
32.1
5.7
6.2

cash-flows.row.cash-at-end-of-period

892.58247153.1249.5
166.2
146.3
82.4
49.1
187
69.5
24.1
43.6
34
25.7
29.6
19.3
28.1
44.2
12.1
6.4

cash-flows.row.cash-at-beginning-of-period

795.75148.8249.5166.2
146.3
82.4
51.2
187
69.5
24.1
43.6
34
25.7
29.6
19.3
28.1
44.2
12.1
6.4
0.3

cash-flows.row.operating-cash-flow

-69.09-69.1-166.6-202.5
-233.3
-250.4
-300
-215.5
-150.5
-100.1
-51.7
-45.8
-33.7
-49.4
-14
-43.4
-36.9
15.2
-33.9
-18.1

cash-flows.row.capital-expenditure

-7.44-7.4-3.8-3.9
-3.2
-20
-6.3
-4.5
-6
-4.8
-0.2
-0.7
-4.3
-1.4
-0.4
-1.8
-2.7
-0.7
-2
-3

cash-flows.row.free-cash-flow

-76.53-76.5-170.3-206.4
-236.5
-270.4
-306.3
-220
-156.5
-105
-51.9
-46.5
-38.1
-50.8
-14.4
-45.2
-39.5
14.5
-35.9
-21.2

Income Statement Row

Amicus Therapeutics, Inc.'s revenue saw a change of 0.213% compared with the previous period. The gross profit of FOLD is reported to be 354.16. The company's operating expenses are 427.65, showing a change of -13.616% from the last year. The expenses for depreciation and amortization are 7.87, which is a -0.372% change from the last accounting period. Operating expenses are reported to be 427.65, which shows a -13.616% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.640% year-over-year growth. The operating income is -73.49, which shows a -0.640% change when compared to the previous year. The change in the net income is -0.359%. The net income for the last year was -151.58.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003

income-statement-row.row.total-revenue

399.36399.4329.2305.5
260.9
182.2
91.2
36.9
5
0
1.2
0.4
18.4
21.4
0.9
64.4
15
1.8
0
0
0
0

income-statement-row.row.cost-of-revenue

39.5145.238.634.5
31
22
14.4
6.2
0.8
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

359.85354.2290.6271
229.8
160.3
76.8
30.7
4.1
0
1.2
0.4
18.4
21.4
0.9
64.4
15
1.8
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

152.38---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-8.69-15.95.36.2
8.8
4.8
-5.6
6
-4.8
-0.1
-0.1
1.7
0
1.6
2.1
2.1
1.5
1.2
0
0
-8.8
0

income-statement-row.row.operating-expenses

431.11427.7495.1471
473.7
461
402.3
241.6
179.2
126
69.9
62.6
71.3
72.3
56.8
70.2
58.9
47.6
46.9
20.8
-8.8
6.6

income-statement-row.row.cost-and-expenses

470.62472.9533.7505.4
504.7
483
416.7
247.8
180
126
69.9
62.6
71.3
72.3
56.8
70.2
58.9
47.6
46.9
20.8
-8.8
6.6

income-statement-row.row.interest-income

7.087.130.5
3.2
10.2
10.5
4.1
1.6
0.9
0.2
0.2
0.3
0.2
0.2
1
0
5.1
2
0.6
0
0

income-statement-row.row.interest-expense

24.1850.137.132.5
22.4
18.9
22.4
17.2
5.4
1.6
1.5
0
0.1
0.1
0.3
0.3
0
-0.3
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-63.86-76.6-37.6-41.6
-30.4
-55.2
-11.7
-225.1
-24.9
-5.4
-0.1
-1.1
0.7
2.8
-0.1
-1.5
4.6
-0.1
-1.2
-0.3
0
-0.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-8.69-15.95.36.2
8.8
4.8
-5.6
6
-4.8
-0.1
-0.1
1.7
0
1.6
2.1
2.1
1.5
1.2
0
0
-8.8
0

income-statement-row.row.total-operating-expenses

-63.86-76.6-37.6-41.6
-30.4
-55.2
-11.7
-225.1
-24.9
-5.4
-0.1
-1.1
0.7
2.8
-0.1
-1.5
4.6
-0.1
-1.2
-0.3
0
-0.2

income-statement-row.row.interest-expense

24.1850.137.132.5
22.4
18.9
22.4
17.2
5.4
1.6
1.5
0
0.1
0.1
0.3
0.3
0
-0.3
0
0
0
0

income-statement-row.row.depreciation-and-amortization

4.137.912.53.8
11.3
-28.2
4.2
3.6
3.2
1.8
1.5
1.7
1.7
1.6
2.1
2.1
1.5
1.2
1
0.7
0
0.1

income-statement-row.row.ebitda-caps

-94.93---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-76.96-73.5-204.4-199.9
-243.9
-300.7
-328.8
-442
-181.9
-130.4
-68.7
-64.2
-52.9
-50.9
-55.8
-7.3
-44
-45.8
-46.9
-20.8
-8.8
-6.6

income-statement-row.row.income-before-tax

-150.1-150.1-242-241.6
-274.3
-355.9
-349.1
-449.1
-203.8
-132.1
-70
-63.1
-52
-48
-56.1
-6.6
-39.4
-41.2
-46.3
-20.6
0
-6.8

income-statement-row.row.income-tax-expense

7.741.5-5.58.9
2.6
0.5
-0.1
-165.1
-3.7
1.5
-1.1
-3.5
-3.2
-3.6
-1.1
0.3
0
0.4
-0.5
-0.6
8.8
0

income-statement-row.row.net-income

-151.58-151.6-236.6-250.5
-276.9
-356.4
-349
-284
-200
-132.1
-68.9
-59.6
-48.8
-44.4
-54.9
-6.6
-39.4
-41.2
-46.3
-20
-8.8
-6.8

Frequently Asked Question

What is Amicus Therapeutics, Inc. (FOLD) total assets?

Amicus Therapeutics, Inc. (FOLD) total assets is 777880000.000.

What is enterprise annual revenue?

The annual revenue is 218583000.000.

What is firm profit margin?

Firm profit margin is 0.901.

What is company free cash flow?

The free cash flow is -0.261.

What is enterprise net profit margin?

The net profit margin is -0.380.

What is firm total revenue?

The total revenue is -0.193.

What is Amicus Therapeutics, Inc. (FOLD) net profit (net income)?

The net profit (net income) is -151584000.000.

What is firm total debt?

The total debt is 445059000.000.

What is operating expences number?

The operating expences are 427651000.000.

What is company cash figure?

Enretprise cash is 246994000.000.